Management of Inflammatory CNV


Visual loss in uveitis can be due to various posterior segment complications that include macular edema, choroidal neovascularization, and epiretinal membrane formation. Choroidal neovascularization (CNV) typically occurs in eyes with posterior uveitis rather than anterior and intermediate uveitis and is a significant cause of visual loss in these eyes. This chapter aims to review the incidence, risk factors, and management of eyes with CNV due to uveitis.


Retinal Pigment Epithelium Laser Photocoagulation Cystoid Macular Edema Choroidal Neovascularization Posterior Uveitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Kempen JH. Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol. 2013;156(3):468–77.e2.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Dhingra N, Kelly S, Majid MA, Bailey CB, Dick AD. Inflammatory choroidal neovascular membrane in posterior uveitis : pathogenesis and treatment. Indian J Ophthalmol. 2010;58(1):3–10.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Neri P, Lettieri M, Fortuna C, Manoni M, Giovaninni A. Inflammatory choroidal neovascularization. Middle East Afr J Ophthalmol. 2009;16(4):245–51.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Hoang QV, Cunningham ET, Sorenson JA, Freund KB. THE “PITCHFORK sign” : a distinctive optical coherence tomography finding in inflammatory choroidal neovascularisation. Retina. 2013;33:1049–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109–14.Google Scholar
  6. 6.
    Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25(2):119–34.Google Scholar
  7. 7.
    van den Bergh H. Photodynamic therapy of age-related macular degeneration: history and principles. Semin Ophthalmol. 2001;16:181–200.CrossRefPubMedGoogle Scholar
  8. 8.
    Reibaldi M, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149(2):307–315.e2.CrossRefPubMedGoogle Scholar
  9. 9.
    Rosenfeld PJ, Saperstein DA, Bressler NM, Reaves TA, Sickenberg M, Rosa Jr RH, et al. Verteporfin in ocular histoplasmosis study group. Photodynamic therapy with verteporfin in ocular histoplasmosis : uncontrolled, open-label-2-year study. Ophthalmology. 2004;111:1725–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Postelmans L, Pasteels B, Coquelet P, et al. Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like). Ocul Immunol Inflamm. 2005;13:361–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Coco RM, de Souza CF, Sanabria MR. Photodynamic therapy for subfoveal and juxtafoveal choroidal neovascularization associated with punctate inner choroidopathy. Ocul Immunol Inflamm. 2007;15:27–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and Intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina. 2008;28(1):71–80.CrossRefPubMedGoogle Scholar
  14. 14.
    Nielsen JS, Fick TA, Saggau DD, Barnes CH. Intravitreal anti–vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina. 2012;32:468–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Arevalo JF, Adan A, Berrocal MH, et al. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina. 2011;31(2):353–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Kramer M, et al. Bevacizumab for choroidal neovascularization related to inflammatory diseases. Retina. 2010;30:938–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29(1):8–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2009;148(2):310–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Menezo V, Cuthbertson F, Downes SM. Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy. Retina. 2010;30:1400–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Cionni DA, Lewis SA, Petersen MR, Foster RE, Reimann CD, Sisk RA, Hutchins RA, Miller DM. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis. Ophthalmology. 2012;119(2):327–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Parodi MB, Iacono P, Kontadakis DS, Zucchiatti I, Cascavilla ML, Bandello F. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol. 2010;128(9):1100–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Ramaiya KJ, Blinder KJ, Ciulla T, Cooper B, Shah GK. Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome. Ophthalmic Surg Lasers Imaging Retina. 2013;44(1):17–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Breger AS, Conway M, del Priore LV, et al. Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis. Arch Ophthalmol. 1997;115:991–6.CrossRefGoogle Scholar
  24. 24.
    Submacular Surgery Trials Research Group. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST report no. 9. Arch Ophthalmol. 2004;122:1597–611.Google Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Shri Bhagwan Mahavir VR ServicesSankara NethralayaChennaiIndia

Personalised recommendations